Published in J Am Acad Dermatol on October 23, 2007
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol (2011) 1.59
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol (2012) 1.46
Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics (2013) 1.32
Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol (2011) 1.18
Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol (2015) 1.14
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol (2010) 1.10
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Biological therapy of psoriasis. Indian J Dermatol (2010) 1.06
Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96
Promising new treatments for psoriasis. ScientificWorldJournal (2013) 0.91
Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol (2014) 0.91
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes (2008) 0.90
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res (2014) 0.90
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol (2014) 0.90
Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Invest Dermatol (2015) 0.89
Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One (2012) 0.89
Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol (2011) 0.88
Adalimumab in dermatology. Br J Clin Pharmacol (2008) 0.86
Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol (2011) 0.86
Psoriasis. Cold Spring Harb Perspect Med (2014) 0.85
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int (2016) 0.85
Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review. Infect Dis Ther (2013) 0.83
Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol (2014) 0.83
Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ (2011) 0.82
Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatol Ther (Heidelb) (2012) 0.81
Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther (2011) 0.81
Long-term efficacy of biologics in dermatology. Dermatol Ther (2009) 0.81
Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. PLoS One (2016) 0.81
Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Rep (2009) 0.80
Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PLoS One (2012) 0.79
Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics (2009) 0.79
Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. Biomed Res Int (2014) 0.79
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol (2015) 0.78
Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res (2014) 0.78
Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol (2014) 0.77
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol (2016) 0.77
Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids Health Dis (2015) 0.76
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol (2015) 0.76
Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. J Eur Acad Dermatol Venereol (2013) 0.76
Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol (2010) 0.76
Treating psoriasis with adalimumab. Ther Clin Risk Manag (2008) 0.76
[Biosimilars versus original biologics : Similarities and differences from development to approval]. Z Rheumatol (2015) 0.76
Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs R D (2016) 0.75
Psoriatic arthritis that responded dramatically when infliximab was switched to adalimumab. Ann Dermatol (2013) 0.75
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. Clin Cosmet Investig Dermatol (2009) 0.75
Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose. Case Rep Dermatol (2011) 0.75
Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol (2009) 0.75
Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open (2016) 0.75
How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Psoriasis Forum (2010) 0.75
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol (2016) 0.75
Biological therapies in moderate and severe psoriasis: perspectives and certainties. J Med Life (2014) 0.75
Psoriasis and Psoriatic Arthritis. J Clin Aesthet Dermatol (2017) 0.75
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature. Clin Cosmet Investig Dermatol (2010) 0.75
Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother (2014) 0.75
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid (2010) 0.75
Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis. Drugs Real World Outcomes (2015) 0.75
Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. Am J Clin Dermatol (2016) 0.75
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. Am J Clin Dermatol (2016) 0.75
Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab. Clin Cosmet Investig Dermatol (2016) 0.75
Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy. Dermatol Ther (Heidelb) (2014) 0.75
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open (2016) 0.75
Immunotargeting in the management of psoriasis. Immunotargets Ther (2013) 0.75
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol (2012) 0.75
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. J Invest Dermatol (2016) 0.75
Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol (2016) 0.75
Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. Curr Neurol Neurosci Rep (2017) 0.75
Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa. Clin Pharmacokinet (2017) 0.75
Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol (2017) 0.75
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med (2004) 3.61
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One (2008) 3.56
Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis (2008) 3.52
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14
Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbiol (2006) 3.01
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet (2012) 2.34
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med (2011) 2.32
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19
Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol (2005) 2.08
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. J Am Acad Dermatol (2008) 1.81
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
The dermatology workforce shortage. J Am Acad Dermatol (2004) 1.76
Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol (2006) 1.69
Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet (2002) 1.67
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat (2007) 1.60
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol (2006) 1.58
Striae and pelvic relaxation: two disorders of connective tissue with a strong association. J Invest Dermatol (2006) 1.55
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol (2011) 1.51
Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res (2004) 1.50
Sex differences in the transmission, prevention, and disease manifestations of sexually transmitted diseases. Arch Dermatol (2006) 1.49
Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol (2005) 1.49
Acne and oral contraceptives: update on women's health screening guidelines. J Am Acad Dermatol (2008) 1.47
Reporting of ethical review of clinical research submitted to the Journal of the American Academy of Dermatology. J Am Acad Dermatol (2006) 1.47
Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol (2011) 1.46
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
US dermatology residents' satisfaction with training and mentoring: survey results from the 2005 and 2006 Las Vegas Dermatology Seminars. Arch Dermatol (2008) 1.44
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther (2013) 1.43
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol (2006) 1.42
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect (2004) 1.42
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Tropical dermatology: viral tropical diseases. J Am Acad Dermatol (2003) 1.40
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
MD/PhDs are more likely than MDs to choose a career in academic dermatology. Dermatol Online J (2008) 1.39
An HIV-Positive Male with a Herald Plaque. Clin Infect Dis (2011) 1.38
Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol (2002) 1.37
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis (2007) 1.37
Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods (2004) 1.37
Tropical dermatology: Venomous arthropods and human skin: Part I. Insecta. J Am Acad Dermatol (2012) 1.35
Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett (2006) 1.34
In vivo reflectance confocal microscopy imaging of melanocytic skin lesions: consensus terminology glossary and illustrative images. J Am Acad Dermatol (2007) 1.33
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2012) 1.33
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol (2005) 1.32
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol (2002) 1.29
Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol (2013) 1.25
The expanding spectrum of eschar-associated rickettsioses in the United States. Arch Dermatol (2010) 1.24
Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol (2008) 1.24
Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol (2008) 1.24
Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol (2002) 1.23
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22
Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol (2013) 1.21
Cutaneous metastasis to the chest wall from prostate cancer. Int J Dermatol (2006) 1.20
Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol (2006) 1.20
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther (2007) 1.17
Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis (2011) 1.17
Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg (2005) 1.16
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis (2005) 1.16
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (2008) 1.15
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol (2004) 1.15
Dermatology residency program characteristics that correlate with graduates selecting an academic dermatology career. Arch Dermatol (2006) 1.14
Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol (2009) 1.12
A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis (2009) 1.11
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol (2010) 1.10
Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol (2006) 1.10
Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med (2008) 1.10
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine (2005) 1.09
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol (2010) 1.08
Herpes simplex viruses 1 and 2. Dermatol Clin (2002) 1.07